检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

A N Boyko,K Z Bakhtiyarova,O V Boyko,V A Dudin,L G Zaslavskii,N A Malkova,E V Parshina,I Ye Poverennova,S A Sivertseva,N A Totolyan,S G Shchur,F A Khabirov,Z A Goncharova,M N Zakharova,D D Bolsun,A V Zinkina-Orikhan,Yu N Lin'kova,T V Chernovskaya,A A Porozova

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova（2023）

引用 0|浏览8
暂无评分
摘要
Treatment with samPEG-IFN-β1a is an effective and safe first-line therapy for relapsing-remitting multiple sclerosis patients.
更多
查看译文
关键词
multiple sclerosis,pegylated IFN-β,relapsing-remitting multiple sclerosis,sampeginterferon-β1a
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要